A new meta‑analysis compared CAR‑T therapies with bispecific antibodies for relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas, synthesizing outcomes across trials to clarify efficacy and safety profiles. The study, presented in the recent literature, provides clinicians and developers with aggregated comparative data on response rates, durability, and toxicity. Authors emphasize cross‑trial heterogeneity and call for head‑to‑head trials to resolve differences in patient selection and long‑term outcomes.